AGLE-103

N/A

Report date: 2023/01/12 15:41:05

Base Information

Drug NameAGLE-103
Drug Alias NameAGLE-103
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsEpidermolysis Bullosa Dystrophica
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAegle Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesAegle Therapeutics
Inactive CompaniesN/A
Active IndicationsEpidermolysis Bullosa Dystrophica
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A